NovaBay stock: buy or sell?

NBY stock price: $0.33 -5.71% At close on May 21st, 2019

Updated on:
May 21st, 2019


Shares of NovaBay ended today at $0.33 and plunged a spooky -5.71%. On May 14th NBY boosted an amazing 60.27%. With Tuesday it's been 5 red days in a row.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States.

Should I buy NovaBay stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

None of our preferred buy setups matches with NovaBay stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is NovaBay Pharmaceuticals stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for NBY stock for the last 30 days.

NovaBay stock analysis

Daily outlook

NovaBay Pharmaceuticals plunged a spooky -5.71% and closed at $0.33.

NovaBay ended today at $0.33 and plunged a spooky -5.71%.

NBY stock chart (daily)

Weekly outlook

NovaBay plummed a scary -15.38% this week. By mid April NBY boosted a dazzling 10.91% in just one week. For 3 weeks in a row, price slid and lost a -71.72%.

NBY stock chart (weekly)

NovaBay stock price history

NovaBay IPO was on October 26th, 2007 at $105.00 per share1. Since then, NBY stock declined a -99.70%, with a yearly average of -9.10%.

1: Adjusted price after possible price splits or reverse-splits.

NovaBay stock historical price chart

NBY stock reached 52-week highs on June at $3.75, and all-time highs 2007-10-26 with a price of 106.25.

NovaBay stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NBY stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price target for NovaBay stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

NovaBay let down analysts on March when it reported an Earnings per Share (EPS) of $-0.09 when the market consensus was $-0.14.
NBY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, NovaBay Pharmaceuticals annual turnover plummed a bloodcurdling -31.39% to $12.51 million USD from $18.23 marked in 2017. In the same way, its profit margin (compared to revenues) plummed to -52.33%, that is $-6.55 million.

NBY annual Sales and Income evolution
2013$3.48 M-$-16.04 M-460.9%-
2014$1.05 M-69.71%$-15.19 M-1441.6%-5.27%
2015$4.38 M315.65%$-18.97 M-433.1%24.87%
2016$12 M171.56%$-13.15 M-110.5%-30.69%
2017$18 M53.23%$-7.40 M-40.6%-43.71%
2018$13 M-31.39%$-6.55 M-52.3%-11.59%

Quarterly financial results

NovaBay Pharmaceuticals posted $3.63 million in sales for 2018-Q4, a 15.37% up compared to previous quarter. Reported quarter income marked $-1.27 M with a profit margin of -34.98%. Profit margin climbed a 13.97% compared to previous quarter when profit margin was -48.95%. When comparing sales to same quarter last year, NovaBay sales marked a spooky correction and plunged a -42.61%. Looking back to recent quarterly results, NovaBay Pharmaceuticals posted 2 positive quarters in a row.
NBY quarterly Sales and Income evolution
2017-Q1$4 M-$-4.01 M-108.4%-
2017-Q2$4 M11.35%$-1.74 M-42.2%-56.61%
2017-Q3$4 M-0.70%$-2.45 M-59.8%40.63%
2017-Q4$6 M54.39%$0.79 M12.6%-132.41%
2018-Q1$3 M-53.34%$-2.15 M-73.0%-371.12%
2018-Q2$3 M-5.19%$-1.59 M-56.9%-26.09%
2018-Q3$3 M12.46%$-1.54 M-48.9%-3.21%
2018-Q4$4 M15.37%$-1.27 M-35.0%-17.56%

NovaBay ownership

When you are planning to buy a company, it's always worth to review its ownership structure.

NovaBay shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 25.87% of all shares.

In case of NovaBay stock, 4.11% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NBY stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related companies:

Market cap$5.7 M$367.4 B$19.1 M$477.5 M$9.5 M
Total shares17.2 M2,660.0 M76.5 M80.9 M12.0 M
Float shares5.3 M2,650.0 M49.3 M49.8 M11.7 M
  - Institutional holdings (%)4.1%69.2%5.0%30.2%14.5%
  - Insider holdings (%)25.9%0.1%28.1%33.0%2.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

NovaBay summary

Tuesday, May 21st, 2019
Day range$0.31 - $0.36
Previous close$0.35
Session gain-5.71%
Average true range$0.20
50d mov avg$1.00
100d mov avg$1.18
200d mov avg$1.38
Daily pattern
Weekly pattern lb06a

NovaBay performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare NovaBay performance to , NanoViricides, SIGA Technologies, Sonoma Pharmaceuticals and Tetraphase Pharmaceuticals:
NBYNovaBay Pharmaceu...-75.37%-72.73%-87.06%
SIGASIGA Technologies-13.62%9.46%-3.44%
SNOASonoma Pharmaceut...-12.22%-7.06%-79.59%
TTPHTetraphase Pharma...-30.00%-54.59%-77.48%

NovaBay competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for NovaBay. We picked 5 companies as NovaBay competitors as they are in the same industry or have similar market objectives.